Norbert VEY
MD
-
Head of the Leukemias Treatment Unit and « Translational Medicine in Hematology » Team at IPC | Co-director of the « Evaluation of Therapeutic Oncology and Hematology » unit at IPC | Professor in hematology at Aix-Marseille University
AMU, IPC
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams’ dynamism and local potential.
Have a look on our testimonies
Marseille Immunopole is born from the will of all partners to do even better and progress faster, and thus allow patients always to keep one step ahead of the disease.
Éric VIVIER
AMU, AP-HM, CIML, INNATE PHARMA
Together, we pursue a simple goal: to better understand the alterations of energetic metabolism in pancreatic cancer cells
Alice CARRIER
AMU, IPC, CRCM
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Delphine BADINAND
APHM
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
Catherine FARNARIER
AP-HM
your commitment to MI